
    
      Design:

      Open phase II study.

      Purpose:

      Response rate for the combination of etoposide, oxaliplatin and capecitabine given every 3
      weeks on an outpatient basis.

      Secondary endpoint are safety, time to progression and survival

      Treatment:

      Etoposide are administered intravenously 100 mg/m2 on day 1 and orally 200 mg/m2 on days 2
      and 3.

      Capecitabine (Xeloda) are administered 1000 mg/m2 twice daily with 12 hours interval for two
      weeks and one week off

      Oxaliplatin are administered intravenously 100 mg/m2 on day 1 in each cycle as a 2 hours
      infusion.

      One cycle is 3 weeks.
    
  